


Fertility Preservation to Cancer Treatment

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.



¹ Provider is defined as physician, pharmacist, nurse practitioner or physician assistant.

² **Important Information (if clinically appropriate)**

- Fertility decisions should be based on an patient's values, beliefs, morals, culture, and religious practices.
- Assessment and informative discussion of fertility desires should be conducted as part of treatment planning options that may impact fertility options.
- Fertility consult criteria:
 - Male greater or equal to 10 years old*
 - Premenopausal female greater or equal to 10 years old*

*See policy assent for pediatric patients

³ **Assess need for:**

- Referral to psychiatry or reproductive medicine psychologist for decision and emotional support.
- Financial counseling regarding fertility preservation by fertility specialist

⁴ **Other Options for Fertility and Parenthood**

- Donor eggs, sperm, and embryos
- Adoption
- Gestational Surrogacy

⁵ **Fertility Preservation Options and length of time needed prior to starting cancer treatment that can impact fertility:**

- Cryopreservation of sperm 1-3 days needed
 - Cryopreservation of embryos 2-3 weeks needed
 - Cryopreservation of oocyte 2-3 weeks needed
- Investigational Fertility Preservation Options**
- Ovarian Suppression up to 10 days needed
 - Cryopreservation of ovarian or testicular tissue

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

APPENDIX A: Sperm Banking and Fertility Consults

Consult for female fertility preservation or counseling for male fertility preservation at MD Anderson

Go to Medications and Orders in OneConnect. Select Ambulatory Referral to Gynecologic Oncology Center and choose Onco Fertility button.

For urgent consults, e-mail: Terri Woodard, MD at tlwoodard@mdanderson.org or Deborah Holman, RN, MSN, WHNP-BC at daholman@mdanderson.org

Sperm banking at Baylor College of Medicine 's Department of Urology

Special Procedures Lab- upfront cost for analysis and one year storage \$550-\$650, without insurance infectious disease testing may be additional.

Phone number 713-798-4027

Lab hours are Monday through Friday, 8 a.m. to 5 p.m.

Patients need to have a cryopreservation referral form completed by their physician To request a referral, call 713-798-4027.

The form should be completed and faxed to Baylor requesting cryopreservation: fax number 713-798-6679.

Same day appointments are often available.

Consult for pediatric fertility preservation or counseling at MD Anderson

Go to Medications and Orders in OneConnect. Select Ambulatory Referral to Pediatrics and choose Onco Fertility button.

Call the Child and Adolescent Center Clinic at 713-792-6610

For inpatient consults and urgent consults, page Donna A. Bell, MSN, RN, NP-C at 713-606-2256 or page John Andrew Livingston, MD at 713-606-1790.

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

APPENDIX B: Patient Education and Websites

MDACC Patient Education (available through patient education online)

Fertility Options for Men and Women

Fertility Options for Men who Need Cancer Treatment

Fertility Options for Women Who Need Cancer Treatment

Pregnancy and Cancer

Pregnancy Test

Preventing Pregnancy during Cancer Treatment

Sexuality and Cancer

Pathfinder--Fertility and Cancer: Provides a list of pamphlets, books and websites that are available to patients.

Websites

www.ReproductiveFacts.org: The patient education website of the American Society for Reproductive Medicine. Under the publications tab, it includes printable informational booklets and fact sheets about a variety of issues including "Age and Fertility," Assisted Reproductive Technologies," "Cancer and Fertility Preservation," "Adoption," and "Third Party Reproduction."

www.livestrong.org: The national LIVESTRONG initiative dedicated to providing reproductive information, support and hope to cancer patients and survivors whose medical treatments present the risk of infertility. In addition to providing patient education and support, it also offers financial assistance for fertility and family building services.

Videos- Fertility Options for Female patients

The Female Reproductive System: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=297C3559-01F5-4F33-B2FC-8B046AEA7C85>

Cancer Treatment and Fertility: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=9B4732BF-6151-4053-A854-4B62F386B711>

Fertility Preservation Before Cancer Treatment: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=97EAAD28-32D9-4FA9-99C1-17C93DAAC0E7>

Family Planning After Cancer Treatment: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=0BE83F30-C1E7-48AF-8035-52EE778DDF63>

Fertility Consultation: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=45EB224B-D593-4B52-8D1D-E9AF5130E97E>

Making Decisions: Patient Stories: <http://www3.mdanderson.org/streams/FullVideoPlayer.cfm?mediaID=98BC2659-724B-4BF8-9CC0-1CC3D1F0177F>

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Aleem, I. S., Jalal, H., Aleem, I. S., Sheikh, A. A., & Bhandari, M. (2009). Clinical decision analysis: incorporating the evidence with patient preferences. *Patient Preference and Adherence*, 3, 21.
- American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. (2013). Mature oocyte cryopreservation: a guideline. *Fertility and Sterility*, 99(1):0015-0282.
- Anderson, R. A., & Wallace, W. H. B. (2013). Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. *Fertility and Sterility*, 99(6), 1469-1475.
- Bedoschi, G., & Oktay, K. (2013). Current approach to fertility preservation by embryo cryopreservation. *Fertility and Sterility*, 99(6), 1496-1502.
- Cakmak, H., & Rosen, M. P. (2013). Ovarian stimulation in cancer patients. *Fertility and Sterility*, 99(6), 1476-1484.
- Campo-Engelstein, L. (2010). Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. *Journal of Clinical Oncology*, 28(8), 1284-1286.
- Chung, K., Donnez, J., Ginsburg, E., & Meirow, D. (2013). Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. *Fertility and Sterility*, 99(6), 1534-1542.
- Cobo, A., Garcia-Velasco, J. A., Domingo, J., Remohí, J., & Pellicer, A. (2013). Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients?. *Fertility and Sterility*, 99(6), 1485-1495.
- Donnez, J. (2013). Introduction: fertility preservation, from cancer to benign disease to social reasons: the challenge of the present decade. *Fertility and Sterility*, 99(6), 1467-1468.
- Georgescu, E. S., Goldberg, J. M., du Plessis, S. S., & Agarwal, A. (2008). Present and future fertility preservation strategies for female cancer patients. *Obstetrical & Gynecological Survey*, 63(11), 725-732.
- Holoch, P., & Wald, M. (2011). Current options for preservation of fertility in the male. *Fertility and Sterility*, 96(2), 286-290.
- Kidger, J., Murdoch, J., Donovan, J. L., & Blazeby, J. M. (2009). Clinical decision-making in a multidisciplinary gynaecological cancer team: a qualitative study. *BJOG: An International Journal of Obstetrics & Gynaecology*, 116(4), 511-517.
- Loren, A. W., Mangu, P. B., Beck, L. N., Brennan, L., Magdalinski, A. J., Partridge, A. H., ... & Oktay, K. (2013). Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *Journal of Clinical Oncology*, 31(19), 2500-2510.
- Marhhom, E., & Cohen, I. (2007). Fertility preservation options for women with malignancies. *Obstetrical & Gynecological Survey*, 62(1), 58-72.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Adolescent and Young Adult (AYA) Oncology.
<http://www.nccn.org/patients/guidelines/aya/index.html>

Continued on next page

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS - continued

Sainio, C., Eriksson, E., & Lauri, S. (2001). Patient participation in decision making about care: The cancer patient's point of view. *Cancer Nursing*, 24(3), 172-179.

Smits, J., Dolmans, M. M., Donnez, J., Fortune, J. E., Hovatta, O., Jewgenow, K., ... & Telfer, E. E. (2010). Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation. *Human Reproduction Update*, 16(4), 395-414.

Tempest, H. G., Ko, E., Chan, P., Robaire, B., Rademaker, A., & Martin, R. H. (2007). Sperm aneuploidy frequencies analysed before and after chemotherapy in testicular cancer and Hodgkin's lymphoma patients. *Human Reproduction*, 23(2), 251-258.

West, E. R., Zelinski, M. B., Kondapalli, L. A., Gracia, C., Chang, J., Coutifaris, C., ... & Woodruff, T. K. (2009). Preserving female fertility following cancer treatment: current options and future possibilities. *Pediatric Blood & Cancer*, 53(2), 289-295.

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice consensus algorithm is based on majority opinion of the Fertility Policy Workgroup and Algorithm by the faculty at the University of Texas MD Anderson Cancer Center. These experts included:

John Araujo, MD
Donna Bell RN, MSN, NP-C
Charles Cowles, MD
Michelle A Fanale, MD
Olga Fleckenstein♦
Colleen Gallagher, PhD
Deborah A Holman, RN, MSN, WHNP-BC
Mary Hughes RN, MSN, APN
Elizabeth Keeler, MD
Jennifer Litton, MD[‡]
John Andrew Livingston, MD
Christopher Logothetis, MD
Andrea Milbourne, MD
Amy Pai, PharmD♦
Kristin A. Simar, RN, ANP-BC
Pamela Soliman, MD
Jerah Thomas, MPH, CHES
Terri Lynn Woodard, MD[‡]

[‡]Core Development Team

♦Clinical Effectiveness Development Team